U.S. Cerebral Palsy Market is expected to grow with a CAGR of 7.7% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/zh/reports/us-cerebral-palsy-market
U.S. cerebral palsy market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.
The major players dealing in the U.S. cerebral palsy market are introducing a strong range of products provider and launching new products, and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.
For instance:
- In 2020, AbbVie Inc. acquired Allergan, a global company that focuses on manufacturing products targeting neuroscience, urology, and other medical fields. The acquisition allowed the company to enhance its therapeutic categories and strengthen the company's financial values, which ultimately accelerated the company's research and developmental activities
AbbVie Inc. is the dominating player in U.S. cerebral palsy market. The other key players existing in the market are Galderma, Viatris Inc., Zydus Pharmaceuticals, Inc. (A subsidiary of Zydus Cadila), Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd, Apotex Inc., Jubilant Cadista (a subsidiary of Jubilant Life Sciences Ltd.), WOCKHARDT, Covis Pharma, VistaPharm, Inc., Elite Pharmaceuticals Inc., Lannett, Par Pharmaceutical among others.
AbbVie Inc.
AbbVie Inc. was founded in the year 2013, headquartered in Illinois, U.S. The company is focused on treating diseases in order to make a remarkable impact on people's lives. The company has several product categories, which are immunology, neuroscience, oncology, virology, general medicine, and contract manufacturing, in which neuroscience is the market-focused category.
The company has a presence across Asia-Pacific, Europe, the Middle East and Africa, Americas. The company also has various subsidiary companies, including Abbott Endocrine Inc. (Delaware), Knoll Pharmaceutical Company (New Jersey), AbbVie S.A. (Argentina), AbbVie Pty Ltd (Australia), AbbVie SA (Belgium), AbbVie SAS (Colombia) Colombia, among others.
- In December 2019, AbbVie Inc. collaborated with Scripps Research in order to boost up the research for new drug discovery targeting a range of diseases, including areas on oncology, immunology among others. As per the collaboration agreement, Scripps Research will conduct pre-clinical research activities for the development of novel therapies. The collaboration helped the company to advance its novel medicines for patients that have ultimately boosted the company's revenue
- In September, AbbVie Inc. has announced the opening of the small molecules active pharmaceutical ingredients manufacturing facility in Singapore. This manufacturing facility will support AbbVie Inc.'s pipeline of oncology and women's health. The company has made an investment of USD 320 million and employed new skilled and technical staff that is more than 250 personnel. The motive behind this expansion was to support patients around the world through their innovative medicines. The expansion helped the company to enhance its product portfolio by manufacturing the novel APIs and will gain recognition through their manufacturing skills as well as API products
GALDERMA
Galderma headquarter is in Texas, the U.S., and was founded in 1981. The company is engaged in providing aesthetics solutions. The company focuses on investing in commercial excellence and innovation to meet the needs of health care professionals, patients, customers, and consumers. The company operates many brands such as Epiduo Forte Gel, Aklief Cream, Soolantra Cream, Mirvaso Gel, Oracea Capsules, Restylane, Dysport, and Sculptra Aesthetic in which the market-focused brand of the company is Dysport.
For instance,
- In January 2021, GALDERMA launched Face for Change, a program designed to make a positive impact in communities around the country in partnership with Dress for Success and The Skin Cancer Foundation. This program launch has created awareness among the customers and boosted the market growth
- In November 2020, GALDERMA announced top-line results from Phase 2 clinical dose-escalating study with Azzalure / Dysport (abobotulinumtoxinA). The conducted trial shows the efficacy and safety of Dysport. This has increased the sales of the products and boosted the market growth
The company has a wide presence across Asia-Pacific, Europe, Middle East, Africa, Latin America, and North America.
Viatris Inc.
Viatris Inc. is headquartered in Pennsylvania, United States, and was incorporated in 1961. The company focused on the healthcare domain with the production of drugs, including prescription generic, branded generic, brand-name, and biosimilar drugs, as well as over-the-counter remedies. The company's market-focused products are DIAZEPAM Tablets USP, BACLOFEN injection, TIZANIDINE Tablets USP, PHENYTOIN Chewable Tablets USP, PHENYTEK (extended phenytoin sodium capsules, USP), CARBAMAZEPINE Tablets, CLONAZEPAM Tablets USP, DIVALPROEX SODIUM Delayed-release Tablets USP, FELBATOL (felbamate), FELBATOL (felbamate), FOSPHENYTOIN SODIUM Injection, LAMOTRIGINE Tablets USP, LEVETIRACETAM in SODIUM CHLORIDE Injection, LEVETIRACETAM Tablets USP, LORAZEPAM Tablets USP, ZONISAMIDE Capsules USP
- In November 2019, Mylan N.V. announced the combination of the company with Upjohn, a division of Pfizer. The new company formed would be named Viatris. The merger of both the company to develop a combined firm has expanded the company's product portfolio leading to increased demand for its product in the market
The company has a presence across North America, Europe, South America, Asia Pacific, Middle East, and Africa. The company also has various subsidiary companies, including Agila Australasia Pty Ltd (Australia), Alphapharm Pty. Ltd. (Australia), Meda Pharmaceuticals Pty Ltd (Australia), Mylan Australia Holding Pty Ltd (Australia), Mylan Health Pty. Ltd. (Australia), and Arcana Arzneimittel GmbH (Austria) among others
